STOCK TITAN

Amphastar Pharmaceuticals (AMPH) Stock News

AMPH NASDAQ

Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.

Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. CFO Bill Peters and Jacob Liawatidewi, EVP of Corporate Administration, will join the analyst-moderated session in London at 12:00 pm GMT. The webcast will be accessible through the company’s investor relations website and available for 30 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) reported third-quarter 2026 revenue of $207.6 million, with higher sales and GAAP earnings than a year earlier. Revenue rose 8% year over year. GAAP net income reached $37.8 million, or $0.87 per diluted share, versus $17.350 million, or $0.37. Adjusted net income was $49.265 million, versus $44.696 million.

BAQSIMI sales rose 10% and Primatene MIST sales increased 9%, while epinephrine and glucagon declined. Gross margin fell to 48.0% from 51.4%, reflecting lower selling prices and higher manufacturing expenses, including remediation costs. General and administrative expenses fell 57%, largely because the prior-year quarter included a litigation provision. The board authorized a $50 million increase in the buyback program on November 4, 2026. Nine-month operating cash flow was $142.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.00%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its third-quarter 2026 financial results after the market closes on November 5, 2026. The results cover the quarter ended September 30, 2026. The company will hold a conference call that day at 2:00 p.m. Pacific Time to discuss the results. A webcast replay will be available on its website within 24 hours after the live call ends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences earnings date
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 4:30 p.m. ET. The presentation will feature CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs and will be webcast on the company’s investor relations website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
none
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) reported second quarter 2026 net revenues of $183.9 million, up 5% year over year. GAAP net income was $30.3 million with diluted EPS of $0.67, while adjusted non-GAAP net income was $40.8 million and adjusted diluted EPS $0.91.

Gross profit rose to $93.5 million with gross margin improving to 50.8% from 49.6%. Product trends included a 3% revenue decline for BAQSIMI® to $45.5 million, an 8% decline for Primatene MIST®, a 42% drop in glucagon, and new ipratropium bromide sales of $8.4 million. “Other products” grew 25% to $66.2 million, driven by iron sucrose, teriparatide, albuterol, phytonadione, sodium bicarbonate, and API sales.

Amphastar achieved the first annual BAQSIMI® net sales milestone of $175.0 million, triggering a $100.0 million payment to Eli Lilly due in the third quarter of 2026. Operating expenses increased, with selling, distribution and marketing, and general and administrative each up 30%, and R&D up 10%. Operating cash flow for the first half of 2026 was $99.2 million. The company also highlighted a pipeline including filed ANDA and biosimilar insulin candidates and multiple proprietary and biosimilar products in development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.90%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its second quarter 2026 financial results, for the period ended June 30, 2026, after the market closes on Thursday, August 6, 2026. The company will host a conference call at 2:00 p.m. Pacific Time, accessible via toll-free and international dial-in numbers and through a webcast on its investor website, where a replay will be available within 24 hours.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences earnings date
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast will be available on the company’s investor relations website for 30 days.

Amphastar develops and sells injectable, inhalation, intranasal, and API products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2026 net revenue of $171.2M, GAAP net income of $6.4M ($0.14 diluted) and adjusted non-GAAP net income of $19.5M ($0.42 diluted). Gross margin fell to 41.1%. The company launched Ipratropium Bromide HFA, in‑licensed a synthetic corticotropin, and holds multiple ANDA/biosimilar filings and pipeline programs. A conference call is scheduled May 7, 2026 at 2:00 p.m. PT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.93%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Bank of America Health Care Conference on May 13, 2026 at 3:00 pm PT. Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will discuss corporate strategy. The webcast is available at Amphastar's investor website and will remain online for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
none
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) will release first quarter 2026 results for the period ended March 31, 2026, after market close on May 7, 2026, and will hold a conference call the same day at 2:00 p.m. PT. The live call and webcast are available on the company's Investors page; a replay will be posted within 24 hours.

Dial-in numbers are toll-free 877-407-0989 or international 201-389-0921. The company develops and sells injectable, inhalation, intranasal, and API products distributed through GPOs, wholesalers, and retailers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences earnings date

FAQ

What is the current stock price of Amphastar Pharmaceuticals (AMPH)?

Amphastar Pharmaceuticals (AMPH) last closed at $29.10.

What is the market cap of Amphastar Pharmaceuticals (AMPH)?

The market cap of Amphastar Pharmaceuticals (AMPH) is approximately $1.2B.